Research Highlights: Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity

Pharmacogenomics

Volumn 13, Issue 13, 2012, Pages 1445-1446

  Peters, Godefridus J ^a   Giovannetti, Elisa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DNA TOPOISOMERASE; FIRTECAN; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ORGANIC ANION TRANSPORTER; ANTINEOPLASTIC AGENT; CATION TRANSPORT PROTEIN;

ABC GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CBORF34 GENE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESEARCH; DRUG UPTAKE; ENZYME INACTIVATION; ETHNIC GROUP; FLJ4 GENE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; KOREAN; MONOTHERAPY; NEUTROPENIA; PDZRN3 GENE; PHARMACOGENOMICS; PLCB1 GENE; PREDICTIVE VALUE; REPLICATION STUDY; SEMA2C GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO GENE; SLCO1B1 GENE; TOXICITY TESTING; TREATMENT RESPONSE; UGT1A1 GENE; FEMALE; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; NOTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CATION TRANSPORT PROTEINS; CISPLATIN; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84867546058     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.134     Document Type: Article

References (9)

1. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol. 24, 4534-4538 (2006)
2. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 (2006)
3. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110, 138-147 (2007)
4. Han JY, Lim HS, Lee SY, Kim HT, Lee JS. Influence of the organic anion transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan- pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59, 69-75 (2008)
5. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004)
6. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81, 42-49 (2007)
7. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann. NY Acad. Sci. 922, 188-194 (2000)
8. Han JY, Shin ES, Lee YS, et al. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-smallcell lung cancer. Pharmacogenomics J. doi:10.1038/tpj.24.
9. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics 13(9), 1073-1086 (2012).